Acorda Therapeutics To Present Phase 3 Fampridine-SR Data at World Congress on Treatment and Research in Multiple Sclerosis Meeting.HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR ACOR Association of Cancer Online Resources ACOR American Center of Oriental Research ACOR Advanced Certificate in Operational Risk ACOR Assistant Contracting Officer Representative ACOR Actual Cost of Repair ACOR Administrative Contracting Officers Representative ) today announced that data from its recently-completed Fampridine-SR Phase 3 trial (MS-F204) will be presented during a poster session at the World Congress in Treatment and Research in MS Meeting (ACTRIMS ACTRIMS Americas Committee for Treatment and Research in Multiple Sclerosis (Canada and US) , ECTRIMS ECTRIMS European Committee for Treatment and Research in Multiple Sclerosis and LACTRIMS) on Saturday, September 20, 2008 in Montreal, Canada. The Company previously announced top-line data from MS-F204 on June 2, 2008, and the poster will provide additional data from that clinical trial. The poster, "Sustained-Release Fampridine Consistently Improves Walking Speed And Leg Strength In Multiple Sclerosis: A Phase 3 Trial," will be presented by Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester The University of Rochester (UR) is a private, coeducational and nonsectarian research university located in Rochester, New York. The university is one of 62 elected members of the Association of American Universities. , from 10:00 to 10:30 a.m. ET. Viewing hours will be from 8:30 a.m. to 12:00 p.m. ET in the Viger Foyer outside Room 517. About Fampridine-SR Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory studies, fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin myelin /my·elin/ (mi´e-lin) the lipid-rich substance of the cell membrane of Schwann cells that coils to form the myelin sheath surrounding the axon of myelinated nerve fibers. , has been damaged. Fampridine-SR recently completed a second Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. to evaluate its safety and efficacy in improving walking ability in people with MS. About Acorda Therapeutics Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. , multiple sclerosis and related nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . The Company's marketed products include Zanaflex Capsules[R] (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda's lead clinical product, Fampridine-SR, recently completed a second Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including delays in obtaining or failure to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Fampridine-SR, the risk of unfavorable results from future studies of Fampridine-SR, Acorda Therapeutics' ability to successfully market and sell Fampridine-SR, if approved, and Zanaflex Capsules, competition, failure to protect its intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from its preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion